EA200200111A1 - Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения - Google Patents
Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их примененияInfo
- Publication number
- EA200200111A1 EA200200111A1 EA200200111A EA200200111A EA200200111A1 EA 200200111 A1 EA200200111 A1 EA 200200111A1 EA 200200111 A EA200200111 A EA 200200111A EA 200200111 A EA200200111 A EA 200200111A EA 200200111 A1 EA200200111 A1 EA 200200111A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- norepinefrin
- application
- selective inhibitors
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 208000020016 psychiatric disease Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 2
- 229960003770 reboxetine Drugs 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Представлены способы и композиции для лечения людей, страдающих от физиологического или психиатрического заболевания, расстройства или состояния или для их предотвращения, в которых полезно ингибирование обратного захвата норэпинефрина. Композиции включают соединение, имеющее фармакологическую селективность серотонин (K)/норэпинефрин (K), равную, по меньшей мере, около 5000. Примеры таких соединений включают ребоксетин и более предпочтительно оптически чистый (S,S) энантиомер ребоксетина. Способы обычно включают введение терапевтического количества данных композиций. Представлены также препараты лекарственного средства, полученные из композиции, и применения композиции в производстве лекарственного средства для лечения людей, страдающих от физиологического или психиатрического заболевания, расстройства или состояния или для их предупреждения.Отчет о международном поиске был опубликован 2002.01.17.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14196899P | 1999-07-01 | 1999-07-01 | |
| US14413199P | 1999-07-16 | 1999-07-16 | |
| US15825699P | 1999-10-06 | 1999-10-06 | |
| US17038199P | 1999-12-13 | 1999-12-13 | |
| PCT/US2000/017256 WO2001001973A2 (en) | 1999-07-01 | 2000-06-22 | Highly selective norepinephrine reuptake inhibitors and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200200111A1 true EA200200111A1 (ru) | 2002-06-27 |
| EA005029B1 EA005029B1 (ru) | 2004-10-28 |
Family
ID=27495506
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200400589A EA006652B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200801806A EA200801806A1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200501496A EA008381B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200700232A EA011094B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200801805A EA200801805A1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200200111A EA005029B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200400589A EA006652B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200801806A EA200801806A1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200501496A EA008381B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200700232A EA011094B1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
| EA200801805A EA200801805A1 (ru) | 1999-07-01 | 2000-06-22 | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения |
Country Status (30)
| Country | Link |
|---|---|
| US (18) | US6465458B1 (ru) |
| EP (3) | EP2090312A1 (ru) |
| JP (3) | JP2003503450A (ru) |
| KR (5) | KR20090087135A (ru) |
| CN (5) | CN1660110A (ru) |
| AR (1) | AR035158A1 (ru) |
| AT (9) | ATE304358T1 (ru) |
| AU (2) | AU771258B2 (ru) |
| BR (1) | BR0012136A (ru) |
| CA (2) | CA2375908C (ru) |
| CL (3) | CL2008002868A1 (ru) |
| CO (1) | CO5190662A1 (ru) |
| CZ (1) | CZ299847B6 (ru) |
| DE (9) | DE60022916T2 (ru) |
| DK (4) | DK1459749T3 (ru) |
| EA (6) | EA006652B1 (ru) |
| ES (9) | ES2258251T3 (ru) |
| GE (1) | GEP20094798B (ru) |
| HU (1) | HUP0201623A3 (ru) |
| IL (3) | IL147246A0 (ru) |
| MX (1) | MXPA02000562A (ru) |
| MY (1) | MY137348A (ru) |
| NO (4) | NO20016406L (ru) |
| NZ (2) | NZ515885A (ru) |
| PE (1) | PE20010684A1 (ru) |
| PL (1) | PL196996B1 (ru) |
| PT (5) | PT1459750E (ru) |
| SK (5) | SK286104B6 (ru) |
| TW (9) | TWI298254B (ru) |
| WO (1) | WO2001001973A2 (ru) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE304358T1 (de) * | 1999-07-01 | 2005-09-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von migränekopfschmerzen |
| EE200200274A (et) * | 1999-12-01 | 2003-06-16 | Ucb, S.A. | Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon |
| ATE312608T1 (de) * | 2000-04-21 | 2005-12-15 | Pharmacia & Upjohn Co Llc | Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom |
| WO2001087308A1 (en) * | 2000-04-21 | 2001-11-22 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
| US20040048860A1 (en) * | 2000-10-31 | 2004-03-11 | Jes Olesen | Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| PL366119A1 (en) * | 2000-11-15 | 2005-01-24 | Eli Lilly And Company | Treatment of anxiety disorders |
| WO2002083141A1 (en) * | 2001-04-17 | 2002-10-24 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| US20060167074A1 (en) * | 2001-06-19 | 2006-07-27 | Norbert Muller | Methods and compositions for the treatment of psychiatric disorders |
| EP1397145B1 (en) * | 2001-06-19 | 2006-09-06 | Norbert Müller | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| ES2287338T3 (es) * | 2001-11-30 | 2007-12-16 | Eli Lilly And Company | Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics. |
| JP2005517647A (ja) * | 2001-12-11 | 2005-06-16 | イーライ・リリー・アンド・カンパニー | ノルエピネフリン再取り込み阻害物質の認知不全処置への使用 |
| US20040102440A1 (en) * | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| CA2475763A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| CA2483093A1 (en) * | 2002-04-24 | 2003-11-06 | Cypress Bioscience, Inc. | Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain |
| WO2003097046A1 (en) | 2002-05-17 | 2003-11-27 | Duke University | Method for treating obesity |
| NZ536415A (en) * | 2002-05-30 | 2006-10-27 | Neurosearch As | Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| MXPA04011916A (es) * | 2002-06-17 | 2005-03-31 | Pharmacia Italia Spa | Sales farmaceuticas de reboxetina. |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| KR20050049476A (ko) * | 2002-08-14 | 2005-05-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 홍조를 치료하기 위한 레복세틴의 용도 |
| DE60324685D1 (de) | 2002-08-23 | 2008-12-24 | Lilly Co Eli | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren |
| GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| WO2004018440A1 (en) * | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | Benzyl morpholine derivatives |
| JP2006504795A (ja) * | 2002-10-03 | 2006-02-09 | サイプレス バイオサイエンス， インコーポレイテッド | 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬 |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| EP2286817A3 (en) * | 2003-01-13 | 2011-06-15 | Edusa Pharmaceuticals, Inc | Method of treating functional bowel disorders |
| KR20050094843A (ko) * | 2003-01-13 | 2005-09-28 | 다이노젠 파마세우티컬스, 인코포레이티드 | 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법 |
| ES2290741T3 (es) * | 2003-04-04 | 2008-02-16 | Dynogen Pharmaceuticals Inc. | Metodo de tratamiento de trastornos del tracto urinario inferior. |
| DE602004012403T2 (de) | 2003-04-29 | 2009-03-19 | Orexigen Therapeutics, Inc., La Jolla | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| WO2004100929A1 (en) | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
| US8158149B2 (en) * | 2004-05-12 | 2012-04-17 | Chelsea Therapeutics, Inc. | Threo-DOPS controlled release formulation |
| WO2004105690A2 (en) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Treatment of chronic pain associated with drug or radiation therapy |
| GB0319793D0 (en) | 2003-08-22 | 2003-09-24 | Lilly Co Eli | Pyridinylmorpholine derivatives |
| CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| WO2005025561A1 (en) * | 2003-09-04 | 2005-03-24 | Synergia Pharma, Inc. | Compositions and methods for orthostatic intolerance |
| CA2537402C (en) * | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| US20050130987A1 (en) * | 2003-10-14 | 2005-06-16 | Wyeth | Methods of treating vasomotor symptoms |
| US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
| GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| DE602004014823D1 (de) * | 2003-12-12 | 2008-08-14 | Lilly Co Eli | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen |
| DE602004019698D1 (de) | 2003-12-23 | 2009-04-09 | Lilly Co Eli | Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| KR100943555B1 (ko) * | 2004-04-30 | 2010-02-22 | 워너-램버트 캄파니 엘엘씨 | 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물 |
| KR100871272B1 (ko) * | 2004-04-30 | 2008-11-28 | 화이자 인코포레이티드 | 모폴린 화합물 |
| MXPA06014389A (es) * | 2004-06-09 | 2007-02-19 | Pfizer | Uso de la reboxetina para el tratamiento del dolor. |
| US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
| US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| DE602005024570D1 (de) | 2004-08-13 | 2010-12-16 | Boehringer Ingelheim Pharma | Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür |
| JP2008514689A (ja) * | 2004-10-01 | 2008-05-08 | ニューロキュア リミテッド | Ａｄｈｄ、ｃｆｓ、ｆｍおよび鬱病の処置のためのロフェプラミンの薬学的な組成物の使用 |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| PL2135603T3 (pl) | 2005-11-22 | 2013-09-30 | Orexigen Therapeutics Inc | Kompozycje i sposoby zwiększania wrażliwości na insulinę |
| US20070253994A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| HRP20120479T1 (hr) * | 2006-06-28 | 2012-07-31 | Chelsea@Therapeutics@Inc | Farmaceutski sastavi sa droksidopom |
| TW200829235A (en) | 2006-11-09 | 2008-07-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications |
| NZ579368A (en) | 2007-03-09 | 2012-03-30 | Chelsea Therapeutics Inc | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
| WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| US20080275131A1 (en) * | 2007-04-30 | 2008-11-06 | Adolor Corporation | Compositions of (-)-e-10-oh-nt and methods for their synthesis and use |
| EP2514417A3 (en) * | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20090233959A1 (en) * | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
| US20090233957A1 (en) * | 2008-02-19 | 2009-09-17 | Adolor Corporation | (-)-beloxepin and methods for its synthesis and use |
| US8940315B2 (en) | 2008-04-18 | 2015-01-27 | Medtronic, Inc. | Benzodiazepine formulation in a polyorthoester carrier |
| US8956642B2 (en) | 2008-04-18 | 2015-02-17 | Medtronic, Inc. | Bupivacaine formulation in a polyorthoester carrier |
| US20110144145A1 (en) | 2008-05-30 | 2011-06-16 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| TWI438190B (zh) * | 2008-07-24 | 2014-05-21 | Theravance Inc | ３－（苯氧基苯基甲基）吡咯啶化合物 |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| WO2010044016A1 (en) * | 2008-10-17 | 2010-04-22 | Pfizer Limited | Novel uses for esreboxetine and racemic reboxetine |
| JP2012524098A (ja) * | 2009-04-15 | 2012-10-11 | セラヴァンス， インコーポレーテッド | ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物 |
| AU2010273645B2 (en) * | 2009-07-13 | 2014-12-04 | Theravance Biopharma R&D Ip, Llc | 3-phenoxymethylpyrrolidine compounds |
| ES2495366T3 (es) | 2009-07-21 | 2014-09-17 | Theravance, Inc. | Compuestos de 3-fenoximetilpirrolidina |
| JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| EP2627630B1 (en) | 2010-10-11 | 2014-12-31 | Theravance Biopharma R&D IP, LLC | Serotonin reuptake inhibitors |
| US8501964B2 (en) | 2010-12-03 | 2013-08-06 | Theravance, Inc. | Serotonin reuptake inhibitors |
| JP5880913B2 (ja) | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| CA2875056C (en) | 2012-06-06 | 2024-03-26 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
| US10526280B2 (en) | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| EP3693020A1 (en) * | 2019-02-08 | 2020-08-12 | Burmaster International Group GmbH | Potassium enriched topical formulations for pain relief and sleep aid |
| AU2020395082A1 (en) * | 2019-12-03 | 2022-06-09 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4465458A (en) * | 1980-03-19 | 1984-08-14 | Matsushita Electric Industrial Co., Ltd. | Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer |
| GB8419683D0 (en) | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
| GB2167407B (en) * | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
| US4596807A (en) | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| ZA921292B (en) | 1991-02-25 | 1993-08-23 | Lilly Co Eli | Treatment of lower urinary tract disorders. |
| US5281624A (en) | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
| TW344661B (en) | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| IL111786A0 (en) | 1993-12-01 | 1995-01-24 | Max Planck Gesellschaft | Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5 |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| ZA958725B (en) | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
| CN1494907A (zh) | 1996-03-25 | 2004-05-12 | 治疗疼痛的药物组合物 | |
| AU2587297A (en) | 1996-03-25 | 1997-10-17 | Eli Lilly And Company | Method for treating pain |
| US5914333A (en) * | 1996-07-31 | 1999-06-22 | Novo Nordisk A/S | Treatment of psychotic disorders |
| US6572880B2 (en) | 1996-10-24 | 2003-06-03 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
| WO1999011208A1 (en) | 1997-08-28 | 1999-03-11 | Williams C Donald | Method and composition for transdermal administration of pharmacologic agents |
| US20020015713A1 (en) | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| US6290986B1 (en) | 1996-10-24 | 2001-09-18 | Pharmaceutical Applications Associates, Llc | Method and composition for transdermal administration of pharmacologic agents |
| EP0856312B1 (de) | 1996-11-27 | 1998-10-14 | Dr. R. Pfleger Chemische Fabrik GmbH | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten |
| KR20000057548A (ko) | 1996-12-13 | 2000-09-25 | 알프레드 엘. 미첼슨 | 광학적 전송물질 및 결합재 |
| EP1007041A4 (en) | 1997-04-11 | 2001-03-07 | Lilly Co Eli | COMPOSITION FOR TREATING PAIN |
| US5942530A (en) | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| JP2001517628A (ja) * | 1997-09-23 | 2001-10-09 | イーライ・リリー・アンド・カンパニー | 注意欠陥／多動障害の治療法 |
| UA57107C2 (ru) | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Лечение заболеваний, сопровождающихся нарушениями поведения |
| UA56257C2 (ru) | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Лечение неадекватного вызывающего поведения |
| JP2001520195A (ja) | 1997-10-17 | 2001-10-30 | イーライ・リリー・アンド・カンパニー | 医薬の増強 |
| WO1999052531A1 (en) | 1998-04-09 | 1999-10-21 | Pharmacia & Upjohn Company | New treatments for nervous disorders |
| US6586427B2 (en) * | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
| IT1305322B1 (it) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Uso di reboxetina per il trattamento di disturbi nervosi |
| ES2232128T3 (es) * | 1998-05-08 | 2005-05-16 | PHARMACIA & UPJOHN COMPANY | Nuevas combinaciones de farmacos de un inhibidor de la recaptacion de noradrenalina (n.a.r.i.), preferentemente reboxetina y pindolol. |
| SK20012000A3 (sk) | 1998-06-29 | 2001-08-06 | Pharmaceuticals Applications Asociates, Llc | Transdermálny prostriedok na zmiernenie bolesti |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| ATE304358T1 (de) * | 1999-07-01 | 2005-09-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von migränekopfschmerzen |
| GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| SE9904750D0 (sv) | 1999-12-23 | 1999-12-23 | Pharmacia & Upjohn Ab | New formulation, use and method |
| WO2001062236A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| US20050096349A1 (en) * | 2003-11-03 | 2005-05-05 | University Of Florida | Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning |
-
2000
- 2000-06-22 AT AT04013383T patent/ATE304358T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020097015714A patent/KR20090087135A/ko not_active Ceased
- 2000-06-22 ES ES04025513T patent/ES2258251T3/es not_active Expired - Lifetime
- 2000-06-22 PT PT04013382T patent/PT1459750E/pt unknown
- 2000-06-22 EA EA200400589A patent/EA006652B1/ru not_active IP Right Cessation
- 2000-06-22 AT AT04025514T patent/ATE305307T1/de not_active IP Right Cessation
- 2000-06-22 CN CN2004101045241A patent/CN1660110A/zh active Pending
- 2000-06-22 US US09/599,213 patent/US6465458B1/en not_active Expired - Lifetime
- 2000-06-22 SK SK1938-2001A patent/SK286104B6/sk not_active IP Right Cessation
- 2000-06-22 SK SK50022-2007A patent/SK286864B6/sk not_active IP Right Cessation
- 2000-06-22 ES ES04013383T patent/ES2247572T3/es not_active Expired - Lifetime
- 2000-06-22 PT PT05111704T patent/PT1632234E/pt unknown
- 2000-06-22 ES ES05111704T patent/ES2285645T3/es not_active Expired - Lifetime
- 2000-06-22 AT AT04025513T patent/ATE319453T1/de not_active IP Right Cessation
- 2000-06-22 GE GEAP200011110A patent/GEP20094798B/en unknown
- 2000-06-22 ES ES04023888T patent/ES2246487T3/es not_active Expired - Lifetime
- 2000-06-22 DE DE60022916T patent/DE60022916T2/de not_active Expired - Fee Related
- 2000-06-22 CN CNB2004101045256A patent/CN1289090C/zh not_active Expired - Fee Related
- 2000-06-22 EA EA200801806A patent/EA200801806A1/ru unknown
- 2000-06-22 PT PT04013383T patent/PT1459751E/pt unknown
- 2000-06-22 SK SK50023-2007A patent/SK286668B6/sk not_active IP Right Cessation
- 2000-06-22 ES ES04013379T patent/ES2239311T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES04025514T patent/ES2246488T3/es not_active Expired - Lifetime
- 2000-06-22 EP EP09161068A patent/EP2090312A1/en not_active Withdrawn
- 2000-06-22 KR KR1020067017835A patent/KR100935277B1/ko not_active Expired - Fee Related
- 2000-06-22 ES ES00941659T patent/ES2258010T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES04013382T patent/ES2242175T3/es not_active Expired - Lifetime
- 2000-06-22 CZ CZ20014625A patent/CZ299847B6/cs not_active IP Right Cessation
- 2000-06-22 CA CA002375908A patent/CA2375908C/en not_active Expired - Fee Related
- 2000-06-22 AU AU56337/00A patent/AU771258B2/en not_active Ceased
- 2000-06-22 HU HU0201623A patent/HUP0201623A3/hu unknown
- 2000-06-22 AT AT04013382T patent/ATE296634T1/de not_active IP Right Cessation
- 2000-06-22 DK DK04013381T patent/DK1459749T3/da active
- 2000-06-22 PL PL352252A patent/PL196996B1/pl not_active IP Right Cessation
- 2000-06-22 DK DK05111704T patent/DK1632234T3/da active
- 2000-06-22 DE DE60026704T patent/DE60026704T2/de not_active Expired - Lifetime
- 2000-06-22 DE DE60022692T patent/DE60022692T2/de not_active Expired - Lifetime
- 2000-06-22 SK SK50024-2007A patent/SK286669B6/sk not_active IP Right Cessation
- 2000-06-22 DE DE60019473T patent/DE60019473T2/de not_active Expired - Lifetime
- 2000-06-22 KR KR1020097015713A patent/KR100948757B1/ko not_active Expired - Fee Related
- 2000-06-22 WO PCT/US2000/017256 patent/WO2001001973A2/en not_active Ceased
- 2000-06-22 PT PT04013379T patent/PT1459748E/pt unknown
- 2000-06-22 CA CA002643231A patent/CA2643231A1/en not_active Abandoned
- 2000-06-22 AT AT05111704T patent/ATE364386T1/de not_active IP Right Cessation
- 2000-06-22 DE DE60035232T patent/DE60035232T2/de not_active Expired - Lifetime
- 2000-06-22 BR BR0012136-3A patent/BR0012136A/pt not_active Application Discontinuation
- 2000-06-22 IL IL14724600A patent/IL147246A0/xx not_active IP Right Cessation
- 2000-06-22 DE DE60026627T patent/DE60026627T2/de not_active Expired - Fee Related
- 2000-06-22 NZ NZ515885A patent/NZ515885A/en unknown
- 2000-06-22 AT AT00941659T patent/ATE320257T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020017016963A patent/KR100704319B1/ko not_active Expired - Fee Related
- 2000-06-22 SK SK50021-2007A patent/SK286667B6/sk not_active IP Right Cessation
- 2000-06-22 CN CN2004101045222A patent/CN1660108A/zh active Pending
- 2000-06-22 CN CN2004101045237A patent/CN1660109A/zh active Pending
- 2000-06-22 EP EP09161069A patent/EP2087892A3/en not_active Withdrawn
- 2000-06-22 PT PT00941659T patent/PT1196172E/pt unknown
- 2000-06-22 EA EA200501496A patent/EA008381B1/ru not_active IP Right Cessation
- 2000-06-22 EP EP00941659A patent/EP1196172B1/en not_active Expired - Lifetime
- 2000-06-22 DE DE60022917T patent/DE60022917T2/de not_active Expired - Fee Related
- 2000-06-22 DK DK04013382T patent/DK1459750T3/da active
- 2000-06-22 EA EA200700232A patent/EA011094B1/ru not_active IP Right Cessation
- 2000-06-22 AT AT04013381T patent/ATE305788T1/de not_active IP Right Cessation
- 2000-06-22 KR KR1020057009371A patent/KR100717660B1/ko not_active Expired - Fee Related
- 2000-06-22 DE DE60020613T patent/DE60020613T2/de not_active Expired - Lifetime
- 2000-06-22 DE DE60023043T patent/DE60023043T2/de not_active Expired - Lifetime
- 2000-06-22 CN CNB008084858A patent/CN1205935C/zh not_active Expired - Fee Related
- 2000-06-22 EA EA200801805A patent/EA200801805A1/ru unknown
- 2000-06-22 MX MXPA02000562A patent/MXPA02000562A/es active IP Right Grant
- 2000-06-22 AT AT04023888T patent/ATE305306T1/de not_active IP Right Cessation
- 2000-06-22 AT AT04013379T patent/ATE292971T1/de not_active IP Right Cessation
- 2000-06-22 JP JP2001507467A patent/JP2003503450A/ja active Pending
- 2000-06-22 DK DK00941659T patent/DK1196172T3/da active
- 2000-06-22 NZ NZ533243A patent/NZ533243A/en unknown
- 2000-06-22 ES ES04013381T patent/ES2246485T3/es not_active Expired - Lifetime
- 2000-06-22 EA EA200200111A patent/EA005029B1/ru not_active IP Right Cessation
- 2000-06-27 MY MYPI20002899A patent/MY137348A/en unknown
- 2000-06-28 PE PE2000000664A patent/PE20010684A1/es not_active Application Discontinuation
- 2000-06-30 AR ARP000103350A patent/AR035158A1/es unknown
- 2000-07-04 CO CO00049691A patent/CO5190662A1/es not_active Application Discontinuation
- 2000-09-05 TW TW094142126A patent/TWI298254B/zh not_active IP Right Cessation
- 2000-09-05 TW TW094142131A patent/TWI294779B/zh active
- 2000-09-05 TW TW094142132A patent/TWI293250B/zh active
- 2000-09-05 TW TW094142128A patent/TWI298255B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124378A patent/TW200922594A/zh unknown
- 2000-09-05 TW TW092137686A patent/TW200407146A/zh unknown
- 2000-09-05 TW TW097124426A patent/TW200914027A/zh unknown
- 2000-09-05 TW TW089113086A patent/TWI245631B/zh not_active IP Right Cessation
- 2000-09-05 TW TW097124457A patent/TW200920378A/zh unknown
-
2001
- 2001-12-14 US US10/020,261 patent/US6703389B2/en not_active Expired - Fee Related
- 2001-12-28 NO NO20016406A patent/NO20016406L/no unknown
-
2002
- 2002-01-04 US US10/099,334 patent/US6642235B2/en not_active Expired - Fee Related
- 2002-01-04 US US10/037,344 patent/US6610690B2/en not_active Expired - Lifetime
- 2002-01-23 US US10/055,663 patent/US6987107B2/en not_active Expired - Fee Related
- 2002-09-26 US US10/255,450 patent/US20030040464A1/en not_active Abandoned
-
2003
- 2003-09-24 US US10/669,611 patent/US20040058925A1/en not_active Abandoned
-
2004
- 2004-01-16 US US10/758,864 patent/US7317011B2/en not_active Expired - Fee Related
- 2004-05-18 AU AU2004202096A patent/AU2004202096B2/en not_active Ceased
-
2006
- 2006-02-07 US US11/349,331 patent/US7338953B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,022 patent/US7241762B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/349,373 patent/US7276503B2/en not_active Expired - Fee Related
- 2006-02-07 US US11/348,948 patent/US20060142289A1/en not_active Abandoned
- 2006-02-22 JP JP2006045459A patent/JP2006143749A/ja active Pending
- 2006-07-28 US US11/460,775 patent/US20060264436A1/en not_active Abandoned
- 2006-08-02 JP JP2006210418A patent/JP2006321815A/ja active Pending
-
2007
- 2007-10-30 US US11/928,980 patent/US20080103147A1/en not_active Abandoned
- 2007-10-30 US US11/928,917 patent/US7723334B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/928,781 patent/US20080103145A1/en not_active Abandoned
- 2007-10-30 US US11/928,812 patent/US20080096890A1/en not_active Abandoned
- 2007-11-20 IL IL187512A patent/IL187512A0/en unknown
- 2007-11-20 IL IL187513A patent/IL187513A0/en unknown
-
2008
- 2008-09-26 CL CL2008002868A patent/CL2008002868A1/es unknown
- 2008-09-26 CL CL2008002866A patent/CL2008002866A1/es unknown
- 2008-09-26 CL CL2008002867A patent/CL2008002867A1/es unknown
-
2009
- 2009-03-18 NO NO20091168A patent/NO20091168L/no not_active Application Discontinuation
- 2009-03-18 NO NO20091158A patent/NO20091158L/no unknown
- 2009-03-18 NO NO20091159A patent/NO20091159L/no unknown
- 2009-04-27 US US12/430,244 patent/US20090247528A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200200111A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| EA199700117A1 (ru) | Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов | |
| TR200100377T2 (tr) | Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. | |
| DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| EA200400302A1 (ru) | Способ лечения первичной бессонницы | |
| HUP0001913A2 (hu) | Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására | |
| PT768083E (pt) | Sertralina para o tratamento de doentes pos-enfarte miocardico | |
| EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders | |
| EA200001058A1 (ru) | Новые способы лечения нервных расстройств | |
| DE60004996D1 (de) | Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen | |
| CA2543986A1 (en) | Norepinephrine reuptake inhibitors and methods of using the same | |
| EA200200846A1 (ru) | Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором | |
| SE9501773D0 (sv) | New use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |